increase in falls among elderly statin-treated patients.
airway reactivity. Our patients have near-perfect immunization status, no overcrowding, high level of education, low cigarette smoke exposure, and excellent pediatric care through physicians who are well aware of current microbial sensitivity patterns. This may be somewhat different from a more rural population in which general practitioners with limited pediatric training may make subspecialty referrals earlier in the course while infection is still persisting, and thus infection as the cause would predominate in their subspecialty clinics. Briefl y, it is likely that prior to referral to a specialist, pediatricians in the United States may be intervening a lot more from weeks 3 to 8 of cough to resolve the cough.
Quality of Workup:
Chang's group performed a selective workup, introducing a selection bias and making the results of prevalence less thorough. 3 Gastroesophageal refl ux disease (GERD) itself is linked to higher prevalence of lower respiratory tract infections and illnesses. So in any persistent lower respiratory tract illness, it becomes important to exclude GERD. Unlike Chang's workup, we performed the same thorough, nonselective investigation on every patient, and it is no surprise that GERD and cough-variant asthma showed up in higher proportions. 1 In our study, for reliability, several of the investigations/treatments required patient cooperation, so our patient group was somewhat older.
Wet Cough May Represent Bacterial Causes:
In our setting, such patients would be fi ltered by the pediatricians and not reach us, the subspecialists. Additionally, a fi ne study by Mello et al 4 has shown that neither the character nor the timing of cough is a good predictor of the cause.
The Comment on Dry Cough Is Provocative:
A number of our patients had dry cough of . 16-weeks duration, even 30-weeks duration, despite interventions. How much longer would one be expected to wait for spontaneous resolution of dry cough? The natural history of short-duration dry cough will obviously be different from an already long-duration dry cough. Our patients had already crossed the 12-weeks mark without resolution of symptoms. Obviously, none of our children had cough scores of zero after 12 weeks.
The Visual Analog Scale: The visual analog scale is a validated tool used to quantify cough very effectively in our setting as well as several other settings. 5 The patient is his or her own control. It is, at worst, a semiobjective measure. This tool works well in our setting but may not be appropriate in other settings, where cough diaries may work better.
Briefl y, our data were obtained in a very thorough manner in a typical urbanրsuburban population in the United States with highquality pediatric care. Thus, the population referred for subspecialty care may be different from a rural population in another country. Finally, the learning objective of this dialogue for the readership should be to most certainly understand the population characteristics in any study before allotting merit and relevance of the data to their own practice. We thank Chang and colleagues for prompting this discussion. 
Statins, Vitamin D, and COPD

To the Editor:
Janda and colleagues, 1 in their review recently published in CHEST (September 2009), highlighted that statin drugs can have a benefi cial role in patients with COPD through their pleiotropic antiinfl ammatory and immune modulatory effects. We suggest that the same immunomodulatory action might be reached in a safer and cheaper way by adequate vitamin D levels.
Vitamin D status is usually divided into three categories, based on serum 25-hydroxyvitamin D [25(OH)D] levels: "defi cient" ( Յ 20 ngրmL), "insuffi cient" (20.1-29.9 ngրmL), and "suffi cient" ( Ն 30 ngրmL). Serum 25(OH)D levels have been decreasing signifi cantly for more than a decade, resulting in a majority of the US population being vitamin D-insuffi cient. Indeed, according to the current defi nition, it is estimated that more than 1 billion people worldwide have impaired serum levels of vitamin D. 2 Patients with COPD should be considered at high risk of vitamin D insuffi ciency because of reduction of outdoor activity, increased glucocorticoids-induced catabolism, impaired activation as a consequence of renal dysfunction, and a lower storage capacity in muscle and fat due to wasting. 2 Indeed, it has recently been found that patients with COPD, without chronic use of systemic glucocorticoids, have increased risk for osteoporosis and low levels of vitamin D, which is correlated with the severity of disease. On the other hand, in clinical practice, muscle complaints are a frequent side effect of statin therapy: statins may exacerbate muscle performance and increase falling risk in elderly subjects. 4 In fact, an important systemic consequence of COPD is muscle weakness, and this is associated with an increased risk of mortality. Vitamin D plays a role in infl uencing skeletal muscle function, with defi ciency resulting in muscle weakness reversed with vitamin D supplementation. Furthermore, vitamin D supplementation has also been shown to reduce the risk of falls among elderly individuals, and it has been suggested that vitamin D defi ciency might explain much of the observed muscle performance decline and
Response
To the Editor:
We thank Mascitelli and colleagues for their response to our article (September 2009). 1 They suggested that because of the side effects of statin drugs, their questionable benefi t in the elderly population, and the increased risk of osteopenia and osteoporosis in COPD, patients with COPD should have adequate levels of vitamin D before considering statin therapy.
Vitamin D therapy in COPD is an intriguing consideration. Given that vitamin D is inexpensive and safe, it would be a desirable treatment option if proven to be effective. We agree that there is an increased risk of osteopenia and osteoporosis in patients with COPD and that patients with vitamin D defi ciency should be supplemented for prevention of this. 2 However, the benefi t of vitamin D on outcomes in COPD remains to be proven, and currently the effectiveness of this therapy is inferential and based on population analyses. 3 We do not know at the present time that vitamin D has the same effect on COPD outcomes such as exacerbation rates, pulmonary function, exercise capacity, COPD mortality, and all-cause mortality as statins may have, as illustrated in our systematic review. Furthermore, there is no evidence that vitamin D therapy would obliviate the reported benefi ts of statin therapy. Vitamin D has been shown to decrease falls and improve muscle strength in the general population, 4 and we acknowledge that statins do have side effects, including myopathy and rhabdomyolysis that may worsen respiratory muscle function in patients with COPD. However, these side effects of statin therapy are very rare. The incidence of statin-induced myopathy, defi ned as any muscle symptom (pain, tenderness, or weakness) and accompanied by a creatine kinase concentration . 10 times normal, is one in 10,000 patients, 5 whereas that of rhabdomyolysis is three in 100,000 patients. 5 Specifi cally in patients with COPD, the only randomized controlled trial identifi ed in our review (Lee et al 6 ) reported that no patients in their study had a statin-induced adverse event.
Mascitelli and colleagues raise an interesting point and highlight the need to consider innovative and multifaceted approaches to the treatment of patients with COPD. We would suggest that vitamin D therapy, as with statin therapy, in COPD requires further investigation but as complementary lines of thought rather than parallel or exclusionary ones. 
